SLFN11 has also been shown to block replication independently of ATR (ataxia telangiectasia and Rad3-related protein) and bind resected DNA ends through replication protein A1 (RPA1) to enhance the drug sensitivity of cancer cells 14, 36, 37. Here, ATR is linked to cancer.